Castle Biosciences INC Form 4 insider transactions

Tiffany Olson, a director at Castle Biosciences, received discretionary stock grants and stock options to address an administrative oversight related to her 2021 compensation.

Castle Biosciences CEO Derek Maetzold sold shares of the company's common stock on June 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Mara G. Aspinall reports the vesting and subsequent disposal of 8,636 restricted stock units of Castle Biosciences on May 23, 2024.

Director Daniel Bradbury reported the vesting of 8,636 Restricted Stock Units (RSUs) into common stock of Castle Biosciences on May 25, 2024.

Director Kim Caple of Castle Biosciences reports the vesting and subsequent disposal of restricted stock units on May 25, 2024.

Director Bradley Cole of Castle Biosciences reports the vesting of restricted stock units and subsequent acquisition of common stock on May 25, 2024.

Director Ellen Goldberg exercised stock options in Castle Biosciences, acquiring 8,636 shares of common stock on May 25, 2024.

Director Harrison Miles of Castle Biosciences reports the vesting and subsequent disposal of 8,636 shares of common stock related to restricted stock units.

Director Tiffany Olson reports the vesting of 8,636 Restricted Stock Units (RSUs) into common stock of Castle Biosciences.

Director Rodney Cotton acquired 8,673 Restricted Stock Units in Castle Biosciences, vesting in full on May 23, 2025.

Director Kim Caple acquired 8,673 Restricted Stock Units (RSUs) of Castle Biosciences, Inc. on May 23, 2024, which will vest on May 23, 2025.

Ellen Goldberg, a director at Castle Biosciences, acquired 8,673 restricted stock units (RSUs) on May 23, 2024, which vest in full on May 23, 2025.

Director Tiffany Olson acquired 8,673 Restricted Stock Units (RSUs) of Castle Biosciences Inc. on May 23, 2024, which vest in full on May 23, 2025.

Director Harrison Miles acquired 8,673 Restricted Stock Units (RSUs) in Castle Biosciences, vesting in full on May 23, 2025.

Director Cole G Bradley acquired 8,673 Restricted Stock Units (RSUs) of Castle Biosciences Inc. on May 23, 2024, which vest in full on May 23, 2025.

Director Daniel Bradbury acquired 8,673 Restricted Stock Units (RSUs) of Castle Biosciences, Inc. on May 23, 2024, which vest in full on May 23, 2025.

Castle Biosciences CEO Derek Maetzold sold shares of CSTL common stock on May 14, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Tiffany Olson exercised stock options to acquire 487 shares of Castle Biosciences (CSTL) common stock on May 10, 2024.

Director Daniel Bradbury of Castle Biosciences sold shares of common stock on May 6, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences CEO Derek Maetzold executed sales of common stock on May 6, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences CEO Derek Maetzold executed sales of common stock on April 23, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Derek Maetzold, CEO of Castle Biosciences, sold shares of common stock on April 12, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Daniel Bradbury of Castle Biosciences sold shares of common stock on April 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Daniel Bradbury executed sales of Castle Biosciences (CSTL) common stock on April 4th and 5th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences CEO Derek Maetzold sold shares of common stock on April 3, 2024, through a pre-arranged Rule 10b5-1 trading plan.

Director Rodney Cotton acquired 15,988 Restricted Stock Units (RSUs) in Castle Biosciences Inc. on March 26, 2024, which vest in three equal annual installments starting March 26, 2025.

Castle Biosciences CEO Derek Maetzold executed sales of common stock on March 20 and 21, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences CEO Derek Maetzold sold shares of common stock on March 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Tobin W. Juvenal, Chief Commercial Officer of Castle Biosciences, reports the acquisition of 55,243 Restricted Stock Units (RSUs) on March 4, 2024, according to a Form 4 filing with the SEC.

Kristen M Oelschlager, COO of Castle Biosciences, reports the acquisition of 55,243 Restricted Stock Units (RSUs) on March 4, 2024, vesting annually starting March 4, 2025.